Louisiana State University Health Sciences Center in New Orleans
Trial Pipeline
Clinical Performance of Nobel N1 System
NCT07280260
Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain
NCT06773715
Investigation Of Bioabsorbable Screws In Pediatric Orthopedic Surgery
NCT06429267
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
NCT05266898
Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?
NCT05663684
New Orleans Pulmonary Hypertension Biobank
NCT03269630
Broccoli Extract Supplementation in Older Adults With Alcohol Use Disorder
NCT05902754
Anti-obesity Pharmacotherapy and Inflammation
NCT05756764
Horizontal Ridge Augmentation With Demineralized Bone Allograft Layered With Xenograft - a Prospective Clinical Study
NCT06342973
The Effect of Increasing Dietary Protein on the Gut Microbiome and Its Metabolites
NCT06677333
Utilization of a Periodontal Endoscope in Nonsurgical Periodontal Therapy
NCT05293301
SBI in Children With d-IBS
NCT02609529
Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients
NCT01941225
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 4 |
Therapeutic Areas
What the Pipeline for Louisiana State University Health Sciences Center in New Orleans Shows
According to the ClinicalTrials.gov registry, Louisiana State University Health Sciences Center in New Orleans is linked to 13 US clinical trials across every stage of research activity. Of those, 6 studies are currently recruiting — about 46% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 38% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Louisiana State University Health Sciences Center in New Orleans reports 4 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Louisiana State University Health Sciences Center in New Orleans is Health Adults with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.